Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Organisation › Details

Celladon Corporation

Celladon is a clinical-stage biotechnology applying its leadership position in the field of cardiovascular gene therapy to develop novel therapies for diseases with tremendous unmet medical needs. Our lead programs target SERCA enzymes which are a family of enzymes that play an integral part in the regulation of intra-cellular calcium in all human cells. Calcium dysregulation is implicated in a number of important and complex medical conditions and diseases, such as heart failure, vascular disease, diabetes and neurodegenerative diseases. MYDICAR, the Company's most advanced product candidate, uses gene therapy to target SERCA2a, which is an enzyme that becomes deficient in patients with advanced heart failure. Celladon has completed enrollment of a 250 patient Phase 2b clinical trial evaluating the efficacy of MYDICAR in reducing the frequency of, or delaying heart failure-related hospitalizations. This randomized, double-blind, placebo-controlled, multinational trial is evaluating a single intracoronary infusion of MYDICAR versus placebo added to a maximal, optimized heart failure regimen in patients with New York Heart Association class III or IV symptoms of chronic heart failure due to systolic dysfunction. The Company has received Breakthrough Therapy designation from the FDA for this MYDICAR program and expects to report results from the Phase 2b clinical trial in April 2015. In addition, Celladon has identified a number of potential first-in-class compounds addressing novel targets in diabetes and neurodegenerative diseases with its small molecule platform of SERCA2b modulators. For more information, please visit www.celladon.com. *

 

Period Start 2014-11-03 existent
Products Industry enzyme replacement therapeutic
  Industry 2 gene therapy cardiovascular disease
Person Person Zsebo, Krisztina (Celladon Corp 201411 CEO)
     
Region Region San Diego, CA
  Country United States (USA)
  Street 11988 El Camino Real
Suite 650
  City 92130-3579 San Diego, CA
  Tel +1-858-366-4288
    Address record changed: 2018-07-24
     
Basic data Employees n. a.
     
    * Document for �About Section�: Lonza Group Ltd.. (11/3/14). "Press Release: Lonza and Celladon Corporation Establish a Strategic Commercial Manufacturing Collaboration for Mydicar". Basel & San Diego, CA.
     
   
Record changed: 2018-10-31

Advertisement

Picture [iito] Männer Ballett 650x80px

More documents for Celladon Corporation


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80




» top